ArticleRMD open2024

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test.

Andrea Di Matteo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.